Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia

Annals of the New York Academy of Sciences

Volumn 1329, Issue 1, 2014, Pages 81-92

  Salzer, Wanda L ^a   Asselin, Barbara L ^b   Plourde, Paul V ^c   Corn, Tim ^d   Hunger, Stephen P ^e  

^a U S ARMY MEDICAL RESEARCH AND MATERIEL COMMAND   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c JAZZ PHARMACEUTICALS   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e University of Colorado Denver and Children s Hospital Colorado   (United States)

Author keywords

Asparaginase; Erwinia chrysanthemi; Hypersensitivity; Leukemia

Indexed keywords

ASPARAGINASE; BACTERIAL ENZYME; PREDNISONE; RECOMBINANT ASPARAGINASE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CYTOTOXICITY; DISEASE FREE SURVIVAL; DRUG HYPERSENSITIVITY; DRUG MONITORING; ENZYME ACTIVITY; ENZYME ISOLATION; ESCHERICHIA COLI; EVENT FREE SURVIVAL; HUMAN; LEUKEMIA REMISSION; PECTOBACTERIUM CHRYSANTHEMI; TREATMENT DURATION; ANIMAL; CLINICAL TRIAL (TOPIC); CROSS REACTION; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; GUINEA PIG; IMMUNOLOGY; ISOLATION AND PURIFICATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TREATMENT OUTCOME; TRENDS;

ANIMALS; ANTINEOPLASTIC AGENTS; ASPARAGINASE; CLINICAL TRIALS AS TOPIC; CROSS REACTIONS; DRUG DISCOVERY; GUINEA PIGS; HUMANS; PECTOBACTERIUM CHRYSANTHEMI; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TREATMENT OUTCOME;

EID: 84910609485     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12496     Document Type: Article

References (83)

1. Bassan, R. & D. Hoelzer. 2011. Modern therapy of acute lymphoblastic leukemia. J. Clin. Oncol. 29: 532-543.
2. Pui, C.H., L.L. Robison & A.T. Look. 2008. Acute lymphoblastic leukaemia. Lancet 371: 1030-1043.
3. Howlader, N. et al., Eds. 2013. "Childhood cancer by the ICCC." In SEER Cancer Statistics Review, 1975-2010. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2010/results_merged/sect_29_childhood_cancer_iccc.pdf. Accessed January 27, 2014.
4. Howlader, N. et al., Eds. 2013. "Leukemia." In SEER Cancer Statistics Review, 1975-2010. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2010/results_merged/sect_13_leukemia.pdf. Accessed February 19, 2014.
5. Nguyen, K., M. Devidas, S.C. Cheng, et al. 2008. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia 22: 2142-2150.
6. Pui, C.H. & W.E. Evans. 2006. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 354: 166-178.
7. Campana, D. 2010. Minimal residual disease in acute lymphoblastic leukemia. Hematology Am. Soc. Hematol. Educ. Program 2010: 7-12.
8. Pui, C.H. & D. Campana. 2000. New definition of remission in childhood acute lymphoblastic leukemia. Leukemia 14: 783-785.
9. Coustan-Smith, E., J. Sancho, M.L. Hancock, et al. 2000. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 96: 2691-2696.
10. Coustan-Smith, E., J. Sancho, F.G. Behm, et al. 2002. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 100: 52-58.
11. Zhou, J., M.A. Goldwasser, A. Li, et al. 2007. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood 110: 1607-1611.
12. Borowitz, M.J., M. Devidas, S.P. Hunger, et al. 2008. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 111: 5477-5485.
13. Cave, H., J. van der Werff ten Bosch, S. Suciu, et al. 1998. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N. Engl. J. Med. 339: 591-598.
14. Eckert, C., A. Biondi, K. Seeger, et al. 2001. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet 358: 1239-1241.
15. Nyvold, C., H.O. Madsen, L.P. Ryder, et al. 2002. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood 99: 1253-1258.
16. Björklund, E., J. Mazur, S. Söderhall & A. Porwit-MacDonald. 2003. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia. Leukemia 17: 138-148.
17. Conter, V., C.R. Bartram, M.G. Valsecchi, et al. 2010. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 115: 3206-3214.
18. Inaba, H., M. Greaves & C.G. Mullighan. 2013. Acute lymphoblastic leukaemia. Lancet 381: 1943-1955.
19. Kidd, J.G. 1953. Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum. J. Exp. Med. 98: 565-582.
20. Broome, J.D. 1961. Evidence that L-asparaginase activity of guinea pig serum is responsible for its antilymphoma effects. Nature 191: 1114-1115.
21. Broome, J.D. 1963. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance. J. Exp. Med. 118: 99-120.
22. Broome, J.D. 1963. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. II. Lymphoma 6C3HED cells cultured in a medium devoid of L-asparagine lose their susceptibility to the effects of guinea pig serum in vivo. J. Exp. Med. 118: 121-148.
23. Mashburn, L.T. & J.C. Wriston, Jr. 1964. Tumor inhibitory effect of L-asparaginase from Escherichia coli. Arch. Biochem. Biophys. 105: 450-452.
24. Boyse, E.A., L.J. Old, H.A. Campbell & L.T. Mashburn. 1967. Suppression of murine leukemias by L-asparaginase. Incidence of sensitivity among leukemias of various types: comparative inhibitory activities of guinea pig serum L-asparaginase and Escherichia coli L-asparaginase. J. Exp. Med. 125: 17-31.
25. Roberts, J., M.D. Prager & N. Bachynsky. 1966. The antitumor activity of Escherichia coli L-asparaginase. Cancer Res. 26: 2213-2217.
26. Schwartz, J.H., J.Y. Reeves & J.D. Broome. 1966. Two L-asparaginases from E. coli and their action against tumors. Proc. Natl. Acad. Sci. U S A 56: 1516-1519.
27. Campbell, H.A., L.T. Mashburn, E.A. Boyse & L.J. Old. 1967. Two L-asparaginases from Escherichia coli B. Their separation, purification, and antitumor activity. Biochemistry 6: 721-730.
28. Hill, J.M., J. Roberts, E. Loeb, et al. 1967. L-asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia. JAMA 202: 882-888.
29. Clarkson, B., I. Krakoff, J. Burchenal, et al. 1970. Clinical results of treatment with E. coli L-asparaginase in adults with leukemia, lymphoma, and solid tumors. Cancer 25: 279-305.
30. Wade, H.E., R. Elsworth, D. Herbert, et al. 1968. A new L-asparaginase with antitumour activity? Lancet 2: 776-777.
31. Wade, H.E., H.K. Robinson & B.W. Phillips. 1971. Asparaginase and glutaminase activities of bacteria. J. Gen. Microbiol. 69: 299-312.
32. Beard, M.E.J., D. Crowther, D.A.G. Galton, et al. 1970. L-asparaginase in treatment of acute leukaemia and lymphosarcoma. Br. Med. J. 1: 191-195.
33. Wang, B., M.V. Relling, M.C. Storm, et al. 2003. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia 17: 1583-1588.
34. Zalewska-Szewczyk, B., A. Gach, K. Wyka, et al. 2009. The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations. Clin. Exp. Med. 9: 113-116.
35. Berenbaum, M.C. 1970. Immunosuppression by L-asparaginase. Nature 225: 550-552.
36. Asselin, B.L., J.C. Whitin, D.J. Coppola, et al. 1993. Comparative pharmacokinetic studies of three asparaginase preparations. J. Clin. Oncol. 11: 1780-1786.
37. Kamisaki, Y., H. Wada, T. Yagura, et al. 1981. Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypolyethylene glycol. J. Pharmacol. Exp. Ther. 216: 410-414.
38. Kamisaki, Y., H. Wada, T. Yagura, et al. 1982. Increased antitumor activity of Escherichia coli. L-asparaginase by modification with monomethoxypolyethylene glycol. Gann 73: 470-474.
39. Dolowy, W.C., D. Henson, J. Cornet & H. Sellin. 1966. Toxic and antineoplastic effects of L-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia. Cancer 19: 1813-1819.
40. Tallal, L., C. Tan, H. Oettgen, et al. 1970. E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children. Cancer 25: 306-320.
41. Sutow, W.W., F. Garcia, K.A. Starling, et al. 1971. L-asparaginase therapy in children with advanced leukemia. The Southwest Cancer Chemotherapy Study Group. Cancer 28: 819-824.
42. Oettgen, H.F., P.A. Stephenson, M.K. Schwartz, et al. 1970. Toxicity of E. coli L-asparaginase in man. Cancer 25: 253-278.
43. Peterson, R.G., R.E. Handschumacher & M.S. Mitchell. 1971. Immunological responses to L-asparaginase. J. Clin. Invest. 50: 1080-1090.
44. Ohnuma, T., J.F. Holland & P. Meyer. 1972. Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. coli. Cancer 30: 376-381.
45. King, O.Y., J.R. Wilbur, D.M. Mumford & W.W. Sutow. 1974. Therapy with Erwinia L-asparaginase in children with acute leukemia after anaphylaxis to E. coli L-asparaginase. Cancer 33: 611-614.
46. Dellinger, C.T. & T.D. Miale. 1976. Comparison of anaphylactic reactions to asparaginase derived from Escherichia coli and from Erwinia cultures. Cancer 38: 1843-1846.
47. Ortega, J.A., M.E. Nesbit, M.H. Donaldson, et al. 1977. L-asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia. Cancer Res. 37: 535-540.
48. Heyn, R., P. Joo, M. Karon, et al. 1975. BCG in the treatment of acute lymphocytic leukemia. Blood 46: 431-442.
49. Sallan, S.E., S. Hitchcock-Bryan, R. Gelber, et al. 1983. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res. 43: 5601-5607.
50. Amylon, M.D., J. Shuster, J. Pullen, et al. 1999. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia 13: 335-342.
51. Pession, A., M.G. Valsecchi, G. Masera, et al. 2005. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J. Clin. Oncol. 23: 7161-7167.
52. Abshire, T.C., B.H. Pollock, A.L. Billett, et al. 2000. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 96: 1709-1715.
53. Silverman, L.B., R.D. Gelber, V.K. Dalton, et al. 2001. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 97: 1211-1218.
54. Schorin, M.A., S. Blattner, R.D. Gelber, et al. 1994. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J. Clin. Oncol. 12: 740-747.
55. LeClerc, J.M., A.L. Billett, R.D. Gelber, et al. 2002. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01. J. Clin. Oncol. 20: 237-246.
56. Rizzari, C., M. Zucchetti, V. Conter, et al. 2000. L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure. Ann. Oncol. 11: 189-193.
57. Duval, M., S. Suciu, A. Ferster, et al. 2002. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood 99: 2734-2739.
58. Moghrabi, A., D.E. Levy, B. Asselin, et al. 2007. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 109: 896-904.
59. Riccardi, R., J.S. Holcenberg, D.L. Glaubiger, et al. 1981. L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res. 41: 4554-4558.
60. Ahlke, E., U. Nowak-Göttl, P. Schulze-Westhoff, et al. 1997. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br. J. Haematol. 96: 675-681.
61. Avramis, V.I., S. Sencer, A.P. Periclou, et al. 2002. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 99: 1986-1994.
62. Müller, H.J., L. Löning, A. Horn, et al. 2000. Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br. J. Haematol. 110: 379-384.
63. Boos, J., G. Werber, E. Ahlke, et al. 1996. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur. J. Cancer 32A: 1544-1550.
64. Vieira Pinheiro, J.P., E. Ahlke, U. Nowak-Göttl, et al. 1999. Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols. Br. J. Haematol. 104: 313-320.
65. Vrooman, L.M., J.G. Supko, D.S. Neuberg, et al. 2010. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr. Blood Cancer 54: 199-205.
66. Pieters, R., S.P. Hunger, J. Boos, et al. 2011. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer 117: 238-249.
67. Woo, M.H., L.J. Hak, M.C. Storm, et al. 2000. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J. Clin. Oncol. 18: 1525-1532.
68. Müller, H.J., R. Beier, L. Löning, et al. 2001. Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br. J. Haematol. 114: 794-799.
69. Willer, A., J. Gerss, T. Konig, et al. 2011. Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials. Blood 118: 5774-5782.
70. Liu, C., J.D. Kawedia, C. Cheng, et al. 2012. Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia 26: 2303-2309.
71. Armstrong, J.K., G. Hempel, S. Koling, et al. 2007. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 110: 103-111.
72. Panetta, J.C., A. Gajjar, N. Hijiya, et al. 2009. Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia. Clin. Pharmacol. Ther. 86: 651-658.
73. Zalewska-Szewczyk, B., W. Andrzejewski, W. Mlynarski, et al. 2007. The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk. Lymphoma 48: 931-936.
74. Panosyan, E.H., N.L. Seibel, S. Martin-Aragon, et al. 2004. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J. Pediatr. Hematol. Oncol. 26: 217-226.
75. Salzer, W.L., B. Asselin, J.G. Supko, et al. 2013. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group. Blood 122: 507-514.
76. Plourde, P.V., S. Jeha, N. Hijiya, et al. 2014. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial. Pediatr. Blood Cancer 61: 1232-1238.
77. Vrooman, L.M., K.E. Stevenson, J.G. Supko, et al. 2013. Postinduction dexamethasone and individualized dosing of Escherichia coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study-Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J. Clin. Oncol. 31: 1202-1210.
78. Tong, W.H., R. Pieters, G.J.L. Kaspers, et al. 2014. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood 123: 2026-2033.
79. Vrooman, L.M., I.I. Kirov, Z.E. Dreyer, et al. 2013. Preliminary results of a pharmacokinetic study of intravenous asparaginase Erwinia chrysanthemi following allergy to E coli-derived asparaginase in children, adolescents, and young adults with acute lymphoblastic leukemia or lymphoblastic lymphoma. Blood 122: 3904.
80. Allas, S., P. Sahakian, I. Fichtner & T. Abribat. 2009. Immunogenicity profile in mice of a pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase. Blood 114: 2034.
81. Allas, S., P. Sahakian, I. Fichtner & T. Abribat. 2009. Pharmacokinetics and pharmacodynamics in mice of a pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase. Blood 114: 2033.
82. Chien, W.-W., C. Lebeux, N. Rachinel, et al. 2012. Anti-leukemic activity of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase on lymphoid cell lines and leukemia-bearing mouse models. Blood 120: 2571.
83. Seibel, N.L., P.G. Steinherz, H.N. Sather, et al. 2008. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 111: 2548-2555.